AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B infection. The company has developed a proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/27/24 | $73,000,000 | Series B |
CDH Investments HanKang Capital  InnoPinnacle Fund Qiming Venture Partners Sherpa Capital YuanBio Venture Capital | undisclosed |
